State policy influence on the early diffusion of buprenorphine in community treatment programs

Substance Abuse: Treatment, Prevention, and Policy

Volumn 3, Issue , 2008, Pages

  Ducharme, Lori J ^a   Abraham, Amanda J ^a  

^a UNIVERSITY OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE; NARCOTIC ANTAGONIST;

ARTICLE; COMMUNITY CARE; GOVERNMENT; HEALTH CARE POLICY; HUMAN; MASS COMMUNICATION; MEDICAID; OPIATE ADDICTION; ORGANIZATION AND MANAGEMENT; PUBLICATION; UNITED STATES;

BUPRENORPHINE; COMMUNITY HEALTH SERVICES; DIFFUSION OF INNOVATION; FORMULARIES; HEALTH POLICY; HUMANS; MEDICAID; NARCOTIC ANTAGONISTS; OPIOID-RELATED DISORDERS; STATE GOVERNMENT; UNITED STATES;

EID: 47949099557     PISSN: None     EISSN: 1747597X     Source Type: Journal    
DOI: 10.1186/1747-597X-3-17     Document Type: Article

References (43)

1. Lamb S Greenlick MR McCarty D Bridging the gap between practice and research: Forging partnerships with community-based drug and alcohol treatment Washington DC: National Academy Press 1998.
2. Sloboda Z Schildhaus S A discussion of the concept of technology transfer of research-based drug abuse prevention and treatment interventions Subst Use Misuse 2002, 37:1079-1087. 10.1081/JA-120004167 12180556
3. Andrzejewski ME Kirby KC Morral AR Iguchi MY Technology transfer through performance management: The effects of graphical feedback and positive reinforcement on drug treatment counselors' behavior Drug Alcohol Depen 2001, 63(2):179-186. 10.1016/S0376-8716(00)00207-6 11376922
4. Liddle HA Rowe CL Quille TJ Dakof GA Mills DS Sakran E Biaggi H Transporting a research-based adolescent drug treatment into practice J Subst Abuse Treat 2002, 22:231-243. 10.1016/S0740-5472(02)00239-8 12072167
5. Martin GW Herie MA Turner BJ Cunningham JA A social marketing model for disseminating research-based treatments to addiction treatment providers Addiction 1998, 93:1703-1715. 10.1046/j.1360-0443.1998.931117038.x 9926533
6. Ball S Bachrach K DeCarlo J Fareninos C Keen M McSherry T Polcin D Snead N Sockriter R Wrigley P Zammarelli L Carroll K Characteristics, beliefs, and practices of community clinicians trained to provide manual-guided therapy for substance abusers J Subst Abuse Treat 2002, 23:309-318. 10.1016/S0740-5472(02)00281-7 12495792
7. Forman RF Bovasso G Woody G Staff beliefs about addiction treatment J Subst Abuse Treat 2001, 21:1-9. 10.1016/S0740-5472(01)00173-8 11516921
8. Mark T Kranzler HR Song X Understanding US addiction physicians' low rate of naltrexone prescription Drug Alcohol Depen 2003, 71(3):219-228. 10.1016/S0376-8716(03)00134-0 12957340
9. Miller WR Mount KA A small study of training in motivational interviewing: Does one workshop change clinician and client behavior? Behav Cogn Psychoth 2001, 29:457-471. 10.1017/S1352465801004064
10. Morgenstern J Morgan TJ McCrady BS Keller DS Carroll KM Manual-guided cognitive-behavioral therapy training: A promising method for disseminating empirically supported substance abuse treatments to the practice community Psychol Addict Behav 2001, 15:83-88. 10.1037/ 0893-164X.15.2.83 11419234
11. Thomas CP Wallack SS Lee S McCarty D Swift R Research to practice: adoption of naltrexone in alcoholism treatment J Subst Abuse Treat 2003, 24:1-11. 10.1016/S0740-5472(02)00319-7 12646325
12. Simpson DD A conceptual framework for transferring research to practice J Subst Abuse Treat 2002, 22:171-182. 10.1016/S0740-5472(02)00231-3 12072162
13. Knudsen HK Roman PM Modeling the use of innovations in private treatment organizations: The role of absorptive capacity J Subst Abuse Treat 2004, 26:353-361. 10.1016/S0740-5472(03)00158-2 14698799
14. Rogers EM Diffusion of Innovations New York: Free Press 1995.
15. Amass L Ling W Freese TE Bringing buprenorphine-naloxone detoxification to community treatment providers: The NIDA Clinical Trials Network field experience Am J Addiction 2004, 13(Suppl):42-66. 10.1080/ 10550490490440807
16. Knudsen HK Ducharme LJ Roman PM Early buprenorphine adoption in substance abuse treatment centers: Data from the public and private sectors J Subst Abuse Treat 2006, 30:363-373. 10.1016/j.jsat.2006.03.013 16716852
17. Koch AL Arfken CL Schuster CR Characteristics of US substance abuse treatment facilities adopting buprenorphine in its initial stage of availability Drug Alcohol Depen 2006, 83:274-278. 10.1016/ j.drugalcdep.2005.12.005
18. Ducharme LJ Knudsen HK Roman PM Trends in the adoption of pharmacotherapies for alcohol dependence J Clin Psychopharm 2006, 26(Suppl 1):13-19. 10.1097/01.jcp.0000246209.18777.14 17114950
19. Fuller BE Rieckman T McCarty D Smith KW Levine H Adoption of naltrexone to treat alcohol dependence J Subst Abuse Treat 2005, 28:273-280. 10.1016/j.jsat.2005.02.003 15857728
20. Knudsen HK Roman PM Ducharme LJ Johnson JA Organizational predictors of pharmacological innovation adoption: The case of disulfiram J Drug Issues 2005, 35:559-574.
21. Knudsen HK Ducharme LJ Roman PM The adoption of medications in substance abuse treatment: Associations with organizational characteristics and technology clusters Drug Alcohol Depen 2007, 87(2-3):164-174. 10.1016/ j.drugalcdep.2006.08.013 16971059 1868517
22. Roman PM Johnson JA Adoption and implementation of new technologies in substance abuse treatment J Subst Abuse Treat 2002, 22:211-218. 10.1016/ S0740-5472(02)00241-6 12072165
23. Knudsen HK Ducharme LJ Roman PM The use of antidepressant medications in substance abuse treatment: The public-private distinction, organizational compatibility, and the environment J Health Soc Behav 2007, 48:195-210. 17583274
24. Substance Abuse and Mental Health Services Administration The DASIS Report: Treatment Admissions with Medicaid as the Primary Expected or Actual Payment Source: 2005. Rockville, MD 2007.
25. Scott WR Institutions and Organizations Thousand Oaks, CA: Sage 1995.
26. DiMaggio PJ Powell WW The iron cage revisited: Institutional isomorphism and collective rationality in organizational fields Admin Sci Quart 1983, 48:147-160.
27. Meyer JW Rowan B Institutional organizations: Formal structure as myth and ceremony Am J Sociol 1977, 83:340-363. 10.1086/226550
28. Koyanagi C Forquer S Alfano E Medicaid policies to contain psychiatric drug costs Health Aff (Millwood). 2005, 24(2):536-544. 10.1377/ hlthaff.24.2.536 15757941
29. McCarty D Frank RG Denmead GC Methadone maintenance and state Medicaid managed care programs Milbank Q 1999, 77:341-362. 10.1111/ 1468-0009.00139 10526548
30. D'Aunno TA Vaughn TE McElroy P An institutional analysis of HIV prevention efforts by the nation's outpatient drug abuse treatment units J Health Soc Behav 1999, 40:175-192. 10.2307/2676372 10467763
31. D'Aunno TA Pollack HA Changes in methadone treatment practices: Results from a national panel study, 1988-2002 J Amer Med Assoc 2002, 288:50-856. 10.1001/jama.288.7.850
32. D'Aunno T Folz-Murphy N Lin X Changes in methadone treatment practices: Results from a panel study, 1988-1995 Am J Drug Alcohol Ab 1999, 25:681-699. 10.1081/ADA-100101886
33. Goldman DP Bhattacharya J Leibowitz AA Joyce GF Shapiro MF Bozette SA The impact of state policy on the costs of HIV infection Med Care Res Rev 2001, 58:31-53. 10.1177/107755870105800408 11236232
34. Heinrich CJ Hill CJ Role of state policies in the adoption of naltrexone for substance abuse treatment Health Serv Res 2008, 43:951-970. 10.1111/ j.1475-6773.2007.00812.x 18454775
35. Ling W Rawson RA Compton MA Substitution pharmacotherapies for opioid addiction: From methadone to LAAM and buprenorphine J Psychoactive Drugs 1994, 26:119-128. 7931856
36. Prendergast ML Grella C Perry SM Anglin MD Levo-alpha-acetylmethadol (LAAM): Clinical, research, and policy issues of a new pharmacotherapy for opioid addiction J Psychoactive Drugs 1995, 27:239-247. 8594167
37. Rawson RA Hasson AL Huber AM McCann MJ Ling W A 3-year progress report on the implementation of LAAM in the United States Addiction 1998, 93:533-540. 10.1046/j.1360-0443.1998.9345338.x 9684391
38. Jaffe JH O'Keeffe C From morphine clinics to buprenorphine: Regulating opioid agonist treatment of addiction in the United States Drug Alcohol Depen 2003, 70(Suppl 2):3-11. 10.1016/S0376-8716(03)00055-3
39. Institute of Medicine Federal Regulation of Methadone Treatment Washington, DC: National Academy Press 1995.
40. Substance Abuse and Mental Health Services Administration Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction (TIP 40). Rockville, MD 2004
41. Substance Abuse and Mental Health Services Administration Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs (TIP 43). Rockville, MD 2005.
42. Substance Abuse and Mental Health Data Archive http://www.icpsr.umich.edu/SAMHDA/
43. Kohler U Kreuter F Data Analysis Using Stata College Station, TX: Stata Corp 2005.